BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) EVP Aby J. Mathew sold 637 shares of BioLife Solutions stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $23.70, for a total value of $15,096.90. Following the sale, the executive vice president now owns 353,118 shares in the company, valued at $8,368,896.60. This represents a 0.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
BioLife Solutions Stock Down 1.9%
Shares of NASDAQ:BLFS opened at $23.30 on Friday. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The stock has a fifty day simple moving average of $22.69 and a two-hundred day simple moving average of $25.00. BioLife Solutions, Inc. has a 12-month low of $18.70 and a 12-month high of $29.55. The stock has a market capitalization of $1.11 billion, a price-to-earnings ratio of -21.98 and a beta of 1.82.
BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.07. The firm had revenue of $23.94 million during the quarter, compared to analyst estimates of $22.22 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. On average, research analysts anticipate that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the company. T. Rowe Price Investment Management Inc. purchased a new stake in shares of BioLife Solutions during the first quarter valued at approximately $30,789,000. Raymond James Financial Inc. bought a new position in BioLife Solutions in the 4th quarter valued at approximately $20,664,000. Massachusetts Financial Services Co. MA purchased a new stake in BioLife Solutions during the 4th quarter valued at $19,805,000. Royal Bank of Canada increased its holdings in shares of BioLife Solutions by 762.8% in the 1st quarter. Royal Bank of Canada now owns 698,251 shares of the medical equipment provider's stock worth $15,948,000 after purchasing an additional 617,320 shares in the last quarter. Finally, Point72 Asset Management L.P. bought a new stake in shares of BioLife Solutions in the 4th quarter worth $11,113,000. 93.24% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
BLFS has been the subject of several recent research reports. HC Wainwright reissued a "buy" rating and set a $30.00 price objective on shares of BioLife Solutions in a research report on Tuesday, May 13th. Wall Street Zen lowered shares of BioLife Solutions from a "hold" rating to a "sell" rating in a research note on Wednesday, May 21st. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $31.17.
Get Our Latest Analysis on BioLife Solutions
BioLife Solutions Company Profile
(
Get Free Report)
BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
